Does Wegovy work for menopausal weight gain?

Why can weight change around menopause?

During perimenopause, the years leading up to the final menstrual period, changing ovarian hormones can coincide with changes in body-fat distribution. Poor sleep, hot flushes, mood symptoms and changes in activity can make weight management harder. Age-related changes in muscle and energy needs may contribute too.

These changes are not a moral failing. They also vary considerably: menopause does not mean everyone will gain a fixed amount of weight. Rapid or unexplained change should be assessed rather than automatically attributed to hormones.

How does Wegovy work?

Semaglutide, the ingredient in Wegovy, mimics glucagon-like peptide-1, or GLP-1, a hormone involved in appetite and blood sugar regulation. It can reduce hunger and increase satisfaction after eating. It also slows stomach emptying, which can contribute to digestive symptoms.

Wegovy does not replace oestrogen and should not be presented as a treatment for hot flushes, vaginal dryness or the whole menopausal transition. Weight management and menopause symptom care can be planned together without pretending that one prescription addresses both.

What can the research tell us?

Randomised trials, which compare treatment groups allocated by chance, support semaglutide for weight management in eligible populations. Those findings are relevant to eligible women in midlife, but they should not be relabelled as dedicated menopause trials or guarantees of an individual result.

Menopause-specific questions, including whether hormone therapy changes the response to semaglutide, need stronger direct evidence. Observational findings can suggest an association but cannot establish that hormone therapy causes greater weight loss. No particular amount of weight loss is promised here.

Who might be eligible?

A clinician should assess the licensed weight-management criteria, weight-related conditions, previous treatment, medicines, nutrition and safety. Menopause on its own is not an indication, and normal midlife body changes should not be medicalised simply for appearance. NHS prescribing arrangements are narrower than simply meeting a product licence and can vary by pathway.

Discuss a plan for review and longer-term care before starting. Appetite suppression should still leave room for adequate nutrition. Dose escalation should follow the prescribed schedule and be reconsidered if side effects interfere with eating or drinking.

Can you use it alongside hormone replacement therapy?

Hormone replacement therapy, or HRT, replaces hormones to treat menopause symptoms; it is not prescribed as a weight-loss treatment. It may make sleep and daily functioning easier when symptoms improve. Wegovy and HRT address different needs, and suitability for each requires an individual review.

Tell your clinician about all oral and non-oral hormone treatments. Vomiting or severe diarrhoea can affect oral medicine absorption. Do not assume the extra oral-contraception instructions for tirzepatide automatically apply to semaglutide. HRT is not contraception, and pregnancy can still be possible in perimenopause. Wegovy should be stopped at least two months before trying to conceive.

How can you protect strength and wellbeing?

Include sufficient protein and other nutrients, and strength-building activity suited to your abilities. Review sleep, menopause symptoms and bone-health needs as part of ordinary midlife care. If fatigue, weakness or food avoidance develops, seek support rather than treating a lower weight as success at any cost.

When should symptoms be checked urgently?

Stop Wegovy and seek urgent medical attention for severe, persistent abdominal pain, especially spreading to the back, with or without vomiting. Persistent vomiting or reduced urine needs prompt assessment for dehydration. New vaginal bleeding after menopause must be checked by a GP, even if it occurs only once; do not assume it is caused by weight loss or dismiss it as a normal hormone change.